Feasibility Study of Asthma Cream
Download in electronic PDF format for $75
Abstract: Asthma, which affects nearly 1 in every 12 people, is a large problem in the U.S. Asthma results in a cost of $56 billion dollars in various hospital bills and inconveniences. Many treatments of asthma use delivery methods (e.g., inhalers, tablets, capsules) that cannot be used by many patients if they have medical conditions that weaken their ability to inhale or swallow. This study’s purpose was to examine the use of topically applied creams as a potential alternative to the use of conventional asthma medications. To test if a cream could work to treat asthma, a cream was developed with a drug normally taken orally that was combined with a cream base that was found most suitable to deliver the drug. The cream was then tested in-situ with mice as the test subject. The cream was applied to the backs of four groups of three mice for 0.5 hours, 1.5 hours, 5 hours, and 7 hours. Blood samples were taken after the respective times, and the quantity of the drug was analyzed in a mass spectrometer. The results showed that a cream delivered enough of an asthma drug to match the bioavailability of an average adult taking montelukast sodium. With this new delivery method, a cream can be used to treat asthma, which can also relieve the discomfort of asthma patients who are unable to use inhaled drugs and even possibly save lives of those unable to use traditional methods of delivery.
Related Keywords:
asthma, reactive airway disease, risk factors, alternative dosage forms, topical preparation, children, leukotrienes, leukotriene inhibitors, montelukast sodium, drug cost, cream bases, skin penetration, transdermal administration, percutaneous absorption
Related Categories:
EXCIPIENTS, PEER-REVIEWED, ALLERGY/IMMUNOLOGY/INFLAMMATION, DOSAGE FORMS/DRUG CARRIERS, RESPIRATION/LUNG/BREATHING
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Feasibility Study of Asthma Cream
Kuang Andrew
|
Mar/Apr 2020
Pg. 163-167
|
In Vitro Skin Penetration and Skin Content of Progesterone from Various Topical Formulations
Heustess Allie, Asbill Scott, Eagerton David, Arnold John
|
Nov/Dec 2014
Pg. 512-515
|
Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin
Le Uyen Minh, Baltzley Sarah, AlGhananeem Abeer
|
Nov/Dec 2018
Pg. 498-503
|
Topical Oil-in-Water Cream Bases, Featured Excipient:
Allen Loyd V Jr
|
Jul/Aug 2002
Pg. 303-304
|
Montelukast Sodium 5-mg Fast-Dissolving Film
Allen Loyd V Jr
|
May/Jun 2016
Pg. 232
|
Compounding Pearls -- Wound Care: Base Selection
Riepl Mike
|
Mar/Apr 2020
Pg. 98-102
|
Compatibility of Estradiol, Estriol, Estrone, Progesterone, and Testosterone Single Formulation in Fitalite, Versatile, or HRT Supreme Cream Base
Polonini Hudson C, Dijkers Eli, Ferreira Anderson O, Zander Clark, Taylor Sarah
|
Jul/Aug 2021
Pg. 336-343
|
Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
|
Sep/Oct 2015
Pg. 357-365
|
Evaluation of Percutaneous Absorption Performance for Human Female Sexual Steroids into Pentravan Cream
Polonini Hudson C, Brandão Marcos Antônio F, Ferreira Anderson O, Ramos Cristiano, Raposo Nádia R B
|
Jul/Aug 2014
Pg. 332-340
|
Case Study: Absorption of Testosterone Cream via Scrotal Delivery
Needham Shawn, Needham Shane
|
Nov/Dec 2018
Pg. 466-468
|
NASEM Report on Compounded Topical Pain Creams
Allen Loyd V Jr
|
Nov/Dec 2020
Pg. 446-448
|
Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy?
Shakshuki Ayah, Agu Remigius U
|
Nov/Dec 2019
Pg. 496-503
|
Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
|
Jul/Aug 2004
Pg. 269-274
|
Progesterone 10% Cream
Allen Loyd V Jr
|
Sep/Oct 2016
Pg. 412
|
Skin Penetration and Antinociception of Topical Gabapentin Formulations
Bryson Evan, Asbill Scott, Sweitzer Sarah
|
Nov/Dec 2014
Pg. 504-511
|
Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
|
Nov/Dec 2022
Pg. 446-466
|
In Vitro Permeability, Irritability, and Release Evaluation of Commonly Used Topical Diclofenac Gel Preparations (1%, 5%, and 10%)
Kohan Hamed Gilzad, Baker David M, Sani Shabnam, Bielecki-Wilken Kathleen A, Ramirez Alfonso
|
Mar/Apr 2021
Pg. 146-155
|
Ex Vivo Percutaneous Absorption of Ketamine, Bupivacaine, Diclofenac, Gabapentin, Orphenadrine, and Pentoxyifylline: Comparison of Versatile Cream vs. Reference Cream
Wang Xuexuan, Black Laura
|
Nov/Dec 2013
Pg. 520-525
|
Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
|
Jul/Aug 2003
Pg. 288-291
|
Basics of Compounding for Cold Sores or Fever Blisters
Allen Loyd V Jr
|
May/Jun 2004
Pg. 206-209
|
Return to Top |